<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122667</url>
  </required_header>
  <id_info>
    <org_study_id>0859-038</org_study_id>
    <secondary_id>MK0859-038</secondary_id>
    <nct_id>NCT01122667</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)</brief_title>
  <official_title>A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in
      subjects with impaired renal function and healthy matched control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0 to infinity)) of anacetrapib</measure>
    <time_frame>through 168 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events</measure>
    <time_frame>through 14 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Part 1 - Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Panel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy matched control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Panel D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy matched control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Panel E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Panel F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy matched control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anacetrapib</intervention_name>
    <description>single dose administration of anacetrapib (MK0859) 100 mg oral tablet</description>
    <arm_group_label>Part 1 - Panel A</arm_group_label>
    <arm_group_label>Part 1 - Panel B</arm_group_label>
    <arm_group_label>Part 2 - Panel C</arm_group_label>
    <arm_group_label>Part 2 - Panel D</arm_group_label>
    <arm_group_label>Part 2 - Panel E</arm_group_label>
    <arm_group_label>Part 2 - Panel F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of reproductive potential test negative for pregnancy and agree to use
             two acceptable methods of birth control throughout the study

          -  Subject is in good health

          -  If Subject is a smoker, smoking is limited to no more than 10 cigarettes per day

        Exclusion Criteria:

          -  Subject has a history of stroke, chronic seizures or major neurological disorder

          -  Subject has a history of cancer

          -  Subject is unable to refrain from or anticipates the use of any prescription or
             non-prescription medication during the study

          -  Subject consumes excessive amounts of alcohol or caffeine

          -  Subject has had major surgery, donated blood or participated in another
             investigational study within the past 4 weeks

          -  Subject is a nursing mother

          -  Subject has had a kidney removed or has a functioning renal transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6.</citation>
    <PMID>24782116</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anacetrapib</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

